(87 days)
No
The description focuses on the mechanical aspects of a stent and delivery system, with no mention of AI or ML capabilities.
Yes
The device is intended for the "palliation of malignant neoplasms in the biliary tree," which involves alleviating symptoms or effects of a disease.
No
The device is a stent and delivery system used for the palliation of malignant neoplasms, indicating a therapeutic rather than diagnostic function.
No
The device description clearly details a physical stent and delivery system, which are hardware components. There is no mention of software as the primary or sole component of the device.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information for diagnosis, monitoring, or screening. This testing is done outside of the body (in vitro).
- Device Description: The Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is a physical device (a stent and its delivery system) that is implanted inside the body (in vivo) to treat a physical obstruction in the biliary tree.
- Intended Use: The intended use is "palliation of malignant neoplasms in the biliary tree," which is a therapeutic intervention, not a diagnostic test performed on a specimen.
The device is a therapeutic medical device used for treatment, not for diagnosing a condition by testing samples.
N/A
Intended Use / Indications for Use
The Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is intended for use in the palliation of malignant neoplasms in the biliary tree.
Product codes
78 FGE
Device Description
The subject PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is a balloon-expandable, stainless steel stent that is provided mounted upon its balloon catheter delivery device. The Cordis JUPITER Balloon Catheters are used for the delivery of the Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent. These balloon catheters are substantially equivalent to the balloon catheter delivery devices used with the aforementioned predicate Cordis device.
The subject PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is advanced over a guidewire through a sheath lumen, via the use of a metal introducer tube accessory, which is also provided with the stent and its delivery system, to an obstruction site in the biliary tree where the balloon is then inflated to expand the stent. After full expansion of the stent, the balloon is then deflated and removed.
The Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is provided sterile and is intended for single use only.
The subject PALMAZ CORINTHIAN Stent is provided in a range of unexpanded lengths from 15 to 18 mm and in a range of expanded diameters from 5 to 6 mm.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
biliary tree
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The safety and effectiveness of the Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System have been demonstrated via data collected from nonclinical tests and analyses.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5010 Biliary catheter and accessories.
(a)
Identification. A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.(b)
Classification. Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
K991674 p. 1/3
510(k) Summary of Safety and Effectiveness
| Submitter: | Cordis Corporation, a Johnson & Johnson Company
40 Technology Drive
Warren, New Jersey 07059 | |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| | Telephone: | (908) 412-7446 |
| | Fax: | (908) 412-3915 |
| Contact Person: | Charles J. Ryan
Manager, Regulatory Affairs
Cordis Corporation, a Johnson & Johnson Company
40 Technology Drive
Warren, New Jersey 07059 | |
| | Telephone: | (908) 412-7446 |
| | Fax: | (908) 412-3915 |
| Date Prepared: | May 14, 1999 | |
| Trade Name: | Cordis PALMAZ CORINTHIAN Transhepatic Biliary
Stent and Delivery System | |
| Common Name: | Biliary Stent and Delivery Catheter | |
| Classification Name: | Biliary Catheter and Accessories (per 21 CFR 876.5010) | |
| Device Classification: | Class II | |
Summary of Substantial Equivalence:
The design, material, components, method of delivery, fundamental technology and intended use featured with the Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System are substantially equivalent to those featured with the predicate Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System (see 510(k) #K990631).
1
K991674 p.2/3
510(k) Premarket Notification
In short, the subject PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System represents a line extension to the predicate Cordis stent and delivery system which allows for the use of an alternate balloon catheter delivery device.
Device Description:
The subject PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is a balloon-expandable, stainless steel stent that is provided mounted upon its balloon catheter delivery device. The Cordis JUPITER Balloon Catheters are used for the delivery of the Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent. These balloon catheters are substantially equivalent to the balloon catheter delivery devices used with the aforementioned predicate Cordis device.
The subject PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is advanced over a guidewire through a sheath lumen, via the use of a metal introducer tube accessory, which is also provided with the stent and its delivery system, to an obstruction site in the biliary tree where the balloon is then inflated to expand the stent. After full expansion of the stent, the balloon is then deflated and removed.
The Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is provided sterile and is intended for single use only.
Intended Use:
The Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System is intended for use in the palliation of malignant neoplasms in the biliary tree.
Technological Characteristics:
The subject PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System incorporates the same method of deployment, fundamental technology and intended use as those found with the predicate Cordis biliary stent and delivery system. The subject PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System features an alternative balloon catheter delivery device that is substantially equivalent to that found with the predicate Cordis biliary stent and delivery system.
The subject PALMAZ CORINTHIAN Stent is provided in a range of unexpanded lengths from 15 to 18 mm and in a range of expanded diameters from 5 to 6 mm.
Performance Data:
The safety and effectiveness of the Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System have been demonstrated via data collected from nonclinical tests and analyses.
2
K991674 p. 3/3
PALMAZ® CORINTIIIAN™ Transhepatic Biliary Stent and Delivery System Cordis Corporation, a Johnson & Johnson Company
510(k) Premarket Notification
A statement of substantial equivalence to another product is required by 21 CFR A statement of substantial equit as the present product can be marketed without ov/.o / and relates only to whenler movel. The present submission is therefore not prior reclassification of cinners appt and is not to be interpreted as an admission or i clared to the coverage of any pringement lawsuit. As the commissioner of the used as CVIdence in a pavent marked ander the Federal Food, Drug
stated, "A determination of substantial equivalence under the Federal started stated, "A decermination of be fact that the product can be lawfully marketed and Cosment Act realers wo the reclassification. This determination is not intended without pre-market upprover on the resolution of patent infringement suits." 42 Federal Register 42, 50 et seq. (1977).
3
Image /page/3/Picture/14 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an image of a stylized eagle with its wings spread.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG 1 2 1999
Mr. Charles J. Ryan Manager, Regulatory Affairs Cordis Corporation, a Johnson & Johnson Company P.O. Box 4917 Warren, New Jersey 07059
Re: K991674
K991674
Cordis PALMAZ® CORINTHIAN™ Transhepatic Biliary Stent and Delivery System Regulatory Class: II 21 CFR §876.5010 Product Code: 78 FGE Dated: May 14, 1999 Received: May 17, 1999
Dear Mr. Ryan:
We have reviewed your Section 510(k) notification of intent to market the device referenced We have reviewed your Section > rocky notined to the indications for use indications for use above and we nave delemined the devices marketed in interstate commerce stated in the enclosure) to legally marketed processor and ments, or to devices that prior to May 26, 1970, the chacment dato of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls of Act (Act). You may, therefore, market and as now , cary of controls provisions of the Act include the Act and the minitations desortoed below. - The good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
The Office of Device Evaluation has determined that there is a reasonable likelihood that this I he Olice of Device Evaluation has determined in the proposed labeling and that such use device will be used for all meended ass not a with Section 513(i)(I)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling
The safety and effectiveness of this device for use in the vascular system have not been established.
Furthermore, the indication for biliary use must be prominently displayed in all labeling including I ulthermore, the midledion for binary box for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations
4
Page 2 -- Mr. Charles J. Ryan
i affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 895.
The County of the formation assumes compliance with the Current Good affecting your device can be found in the Coundiance with the Current Good
A substantially equivalent determination assumes compliance with the Current Regulation ( A substantially equivalent determination assumes complanoc while many of them Regulation (QS) for
Manufacturing Practice requirements, as set forth in the Quality System Regu Manufacturing Practice requirements, as set lordin and that, through periodic QS
Medical Devices: General regulation (21 CFR Part 820) and that, through periodic of a Medical Devices: General regulation (PDA) will vifty such assumptions. Failure to
inspections, the Food and Drug Administration (FDA) will verify such assumptions) Follur inspections, the Food and Drug Administration (FDA) will vents comply with the GMP regulation may result in the Federal Register. Please note: this further announcements concerning your devices in the regence. response to your premarket notification submission and the Electronic Product Ration
under sections 531 through 542 of the Act for devices under the Electronic Product Radiat under sections 551 through overal laws or regulations.
The FDA finding of substantial equivalence of your device to a legally marketed proceed to the market. This The FDA finding of substantial equivalence of your device to proceed to the market. This
results in a classification for your device and permits your device to proceed to th results in a classification for your device and penines your device in your 510(k) premarket
letter will allow you to begin marketing your device as described. letter will allow you to begin marketing your device as associety of the subscribed.
notification if the limitation statement above is added to your labeling, as described.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act.
The Act. In and Management before these limitations are modified in any way o Please note that the above labeling limitations are required by Boals. For ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) from the device's labeling.
If you desire specific information about the application of other labeling requirements to your If you desire specific information about the application of our and devices), please contact
device (21 CFR Part 801 and 2011 11/16 - Aditionally for guestions on the promoti device (21 CFR Part 801 and additionally 809.10 lot millio cultures on the promotion and the Office of Compliance at (301) 394-4610. Administrat (301) 594-4639. Also,
advertising of your device, please contact the Office of Compliance at (301) 594-4639. advertising of your device, please contact the online of estage to premarket notification"
please note the regulation entitled, "Misbranding by reference to premarket notific please note the regulation entitled, "Misor for responsibilities under the Act may be
(21 CFR 807.97). Other general information on your responsibilities under the Act may be (21 CFR 807.97). Other general miormation on your sistem at its toll-free number
obtained from the Division of Small Manufacturers Assistance at its toll-free number obtained from the Driston of S597 or at its Internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Sumafro
Susan Alpert, Ph.D., M Director Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Special 510 (k) Number:
Device Name:
Cordis PALMAZ CORINTHIAN Transhepatic Biliary Stent and Delivery System
Indications For Use:
The Cordis PALMAZ CORNTHIAN Stent and Delivery System is indicated for the palliation
of malignant neonlasms in the bilians tree of malignant neoplasms in the biliary tree.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER
PAGE IF NEEDED) PAGE IF NEEDED)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use OR Over-The-Counter Use _____________ (Per 21 CFR 801.109) (Optional Format 1-2-96) (Division Sign-Off) f Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number 991674 :